Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatou Proliferation Original Reearch Article

Purpoe To clarify the efficiency of combined therapy with intravitreal bevacizumab injection and photodynamic therapy (PDT) in patient with retinal angiomatou proliferation (RAP). Deign Retropective, obervational, conecutive cae erie. Method We retropectively reviewed 11 conecutive eye with RAP (10 patient; ix men, four women) treated with intravitreal bevacizumab injection and PDT. Patient ranged in age from 63 to 89 year old (average, 79 year). No patient had undergone previou treatment, and patient were followed for at leat ix month. PDT wa applied one or two day after the intravitreal bevacizumab (1.25 mg) injection. Reult The mean bet-corrected viual acuity (BCVA) level at baeline and one, three, and ix month after treatment were 0.16, 0.27, 0.31, and 0.29, repectively. A ignificant improvement in the mean BCVA wa oberved one, three, and ix month after intravitreal bevacizumab injection and PDT (P < .01). The mean improvement in BCVA ix month from baeline wa 2.64 line. The BCVA at ix month improved in ix eye (54.5%, improved by three line or more) and wa table in five eye (45.5%). No patient had a decreae in the BCVA of three or more line during any ix month. The central retinal thickne ignificantly decreaed from 496 ± 189 μm to 175 ± 33 μm at ix month (P < .001). No patient required retreatment during any ix month. No complication uch a evere viion lo, endophthalmiti, or ytemic event developed. Concluion Combined intravitreal bevacizumab and PDT for RAP effectively maintained or improved VA and reduced or eliminated edema in the hort-term.